Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Monoclonal antibodies used to prevent COVID-19 in immunocompromised people aren’t active against new virus variants.
Before they get COVID, people over 65 should have a plan for accessing antiviral treatment.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The prevalence of abnormal liver tests in people hospitalized with COVID-19 is higher than previously found.
More diversity would help doctors determine whether coronavirus treatments and vaccines will work for all population groups.
Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.
FDA grants emergency use authorization, but randomized clinical trials of the antiviral drug show mixed results.
Gilead Sciences is giving its antiviral remdesivir to nearly 1,000 people as part of two clinical trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.